Lack of Specific Immune Response after Five Doses of mRNA SARS-CoV-2 Vaccine in a Patient with CD4<sup>+</sup> T-Cell Lymphopenia but Preserved Responses to CMV
Trinidad Alba-Cano,
Eduardo Fernández-Cruz,
Roberto Alonso,
Sara Muñoz-Gómez,
Rebeca Pérez de Diego,
Elena García Martínez,
Paloma Sánchez-Mateos,
Joaquín Navarro Caspistegui,
Mónica Martín López,
Juana Gil-Herrera
Affiliations
Trinidad Alba-Cano
Division of Immunology, Hospital General Universitario “Gregorio Marañón”, 28007 Madrid, Spain
Eduardo Fernández-Cruz
Division of Immunology, Hospital General Universitario “Gregorio Marañón”, 28007 Madrid, Spain
Roberto Alonso
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain
Sara Muñoz-Gómez
Division of Immunology, Hospital General Universitario “Gregorio Marañón”, 28007 Madrid, Spain
Rebeca Pérez de Diego
Laboratory of Immunogenetics of Human Diseases, Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz Hospital, 28046 Madrid, Spain
Elena García Martínez
Division of Immunology, Hospital General Universitario “Gregorio Marañón”, 28007 Madrid, Spain
Paloma Sánchez-Mateos
Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense, 28040 Madrid, Spain
Joaquín Navarro Caspistegui
Division of Immunology, Hospital General Universitario “Gregorio Marañón”, 28007 Madrid, Spain
Mónica Martín López
Division of Immunology, Hospital General Universitario “Gregorio Marañón”, 28007 Madrid, Spain
Juana Gil-Herrera
Division of Immunology, Hospital General Universitario “Gregorio Marañón”, 28007 Madrid, Spain
Immunogenicity of SARS-CoV-2 mRNA vaccines is highly heterogeneous in patients with inborn errors of immunity (IEIs). This case report analyzes the immune response to mRNA COVID-19 two-dose primary vaccination followed by three boosters in an IEI patient with marked CD4+ T-cell cytopenia and diminished thymic output, in comparison with that raised against latent, chronic cytomegalovirus (CMV) infection. Serum IgG antibodies anti-spike (S) protein of SARS-CoV-2 and anti-CMV were both determined by chemiluminescent microparticle immunoassays (CMIAs). SARS-CoV-2 and CMV memory CD4+ T-cell responses were simultaneously evaluated in vitro using an activation-induced marker (AIM) assay via multicolor flow cytometry. Throughout the 2-year follow-up that included the administration of five doses of SARS-CoV-2 mRNA vaccines, cellular anti-SARS-CoV-2-specific responses remained consistently negative, with extremely weak humoral responses, while the patient showed in vitro persistent CD4+ T-cell reactivity to CMV peptides and high-IgG CMV-specific titers. The assessment of immune responses to vaccines and prevalent viruses is essential in IEI patients in order to take adequate preventive measures.